General
The Future Synthetic Drugs Of Abuse
Designer Drugs - part 1 of 3
By Donald A. Cooper
From The DEA
It seems likely that primitive man wished at times to escape his reality and most probably found some natural drug to facilitate this desire.
In fact, abuse of the coca leaf and the opium poppy is thought to have been practiced for at least the last 3400 years and the use of peyote may have been known as early as 1000 BC.
Perhaps due in part to the long history of opiate products, one of the first derivatives of a natural drug to be used pharmaceutically was heroin.
The acceptance of heroin as a pharmaceutical was primal in establishing the concept that certain structural modifications of physiologically active compounds can result in new compounds which cause biological responses which are not only similar, but are enhanced as compared to those of the parent compounds.
Other works such as the structural elucidation of mescaline and the preparation of N-methyl and N-acetyl derivatives of mescaline has served to strengthen this concept and to broaden the scope of permissible derivatives.
In the ensuing years much knowledge has been gained regarding biologically useful derivatives of the naturally occurring drugs but, most importantly, the structures of the alkaloids and the protoalkaloids have, one by one, been elucidated.
This knowledge has then allowed researchers of recent times to deduce many of the structure relationships associated with specific biological responses.
The sum of this hard-won knowledge allows one to produce pharmaceutically useful compounds, which have no counterpart in nature, from off the shelf chemicals.
Unfortunately there are those people who would take this body of knowledge and, rather than use it for the enhancement of medical science, use it for their own financial gain. Individuals such as these have created the so-called designer drug phenomenon.
Henderson (1986) first described a synthetic drug as one which was designed by a clandestine chemist to produce a certain pharmacological response.
However, today designer drugs are universally understood to belong to a group of clandestinely produced drugs which are structurally and pharmacologicaly very similar to a controlled substance but are not themselves controlled substances.
The Drug Enforcement Administration (DEA) has noted that the designer drug terminology tends to cast a somewhat glamorous aura onto the concept, and as a result, the DEA feels that it would be wise to refer to these compounds in some other manner and suggests the use of the term Controlled Substance Analogs (CsA).
In October of 1987 the United States Government amended the Controlled Substance Act in an effort to curtail the illicit introduction of new CsA's.
This amendment states that any new drug which is substantially similar to a controlled substance currently listed under the Code of Federal Regulations (CFR), Schedule I or II, and has either pharmacological properties similar to a Schedule I or II substance or is represented as having those properties, shall also be considered a controlled substance and will be placed in Schedule I.
The amendment further contains provisions which exempt the legitimate researcher as well as compounds that are already being legally marketed from the provisions of the amendment.
Since the CsA amendment has yet to be tested in a court of law, it is much too early to say how successful it will be in limiting the spread of the CsA phenomena.
However, it is safe to assume that there will be those who believe that they can manage to evade the provisions of the CsA amendment, and much of the world has not yet even attempted to find a litigious solution to the problem of CsA's.
Therefore, an attempt to identify those CsA's which would be logical candidates for synthesis by a clandestine chemist is still a pertinent exercise.
Hallucinogens
A great many compounds, when taken in sufficient quantity, will alter one's perception of reality. For the purposes of this paper, the term hallucinogen is reserved for those compounds that are characterized by the predominance of their actions on mental and psychic functions (Brown 1972).
Hallucinogens can be classified according to structural similarities into four groups of compounds and into one group containing miscellaneous structures.
The classifications are: indoles, phenylalkylamines, piperidyl benzilate esters, cannabinoids and miscellaneous.
The piperidyl benzilate esters have been extensively studied and relationships between psychotomimetic activity and chemical structure have been established (Abood et al. 1959; Abood and Biel 1968).
The N-methyl and N-ethyl-3-piperidyl benzilate esters are controlled substances and are listed under the CFR Schedule I as hallucinogens. Benactyzine is a noncontrolled drug which is used medically as an antagonist to cholinergic nerve fibers (Biel et al. 1962).
It appears that the pharmacological effects of the piperidyl benzilate esters may not be conducive to a good trip for the user. Brown describes the pharmacological effects by explaining how thought processes are severely disrupted.
He reports that speech is disorganized and incoherent, and that confusion, disorientation, and amnesia occur often and may be long lasting (Brown 1972). Perhaps these compounds should not be classified as hallucinogens but rather as incapacitating agents.
Additionally, although the pharmacological effects of the piperidyl benzilates have been compared to those elicited by phencyclidine (PCP), there is no evidence to suggest any significant abuse of these compounds. Therefore, no further discussion will be given to the piperidyl-benzilate esters.
Given the world wide ready availability of marijuana, it is somewhat difficult to produce a viable argument for making CsA's of cannabinoids. However, ten years ago (1978) an attempt to produce CsA's from cannabis extracts was encountered in the Jacksonville, Florida area.
In this case a concentrated extract of cannabis had been obtained by a soxhlet extraction. The extract had been acetylated with acetic anhydride, and in the final step, the excess acetic anhydride removed by distillation (reference is unretrievable due to its appearance in an underground periodical).
The product contained neither quantities of nonderivatized cannabinoid nor any identifiable plant fragments Since this single instance, no acetalaced cannabinoid samples have been reported by a DEA laboratory.
Therefore, this instance is assumed to represent an isolated occurrence and as such, will serve to terminate our discussion of cannabinoid CsA's.
Under the heading miscellaneous, one must include nearly any ingestible compound known to man, as any substance taken at toxic levels will alter one's perception of reality.
Obviously a discussion of all such compounds as models for CsA hallucinogens is not within the scope of this article.
However, the compound known as phencyclidine (PCP or N-(1-phenylcyclohexyl)piperidine), although developed by Parke Davis and Company (Rochester, Michigan) as an anesthetic, does produce psychotomimetic effects and is widely abused in the United States.
It is listed in the CFR under Schedule II, and two of its homologs and one analog are listed under Schedule I.
Therefore, in the following discussions, the indoles, the phenylalkylamines and PCP will be considered as possible candidates for hallucinogenic CsA's.
Indoles
The literature covering indole chemistry is huge and diverse. Over 500 naturally occurring indole alkaloids were known by 1972 and accounted for nearly one fourth of all alkaloids known at that time (Robinson 1968).
By 1980, the number of known indole alkaloids had risen to approximately 1200 (Kisakurek and Hesse 1980). Today there have been many more indoles added to the list of naturally occurring alkaloids.
These alkaloids include such pharmacologicaly and structurally diverse compounds as tryptophan (essential amino acid), reserpine (tranquilizer), strychnine (stimulant-convulsant) harmaline (hallucinogen), serotonin (anticholinesterase/monoamine oxidase inhibitor), ergometrine (oxytocic), vinblastine (antitumor agent), and psilocybin (hallucinogen).
Only nine compounds containing the indole nucleus are controlled substances under the United States Federal Statutes.
Three of these compounds are classified as ergot alkaloids, five are simple 3-(2-ethylamino)indoles, and one is the pentacyclic alkaloid, ibogaine.
The ergot alkaloids are lysergic acid, lysergic acid amide, and lysergic acid diethylamide (LSD). The five controlled indolealkylamines are N,N-dimethyltryptamine (DMT), N,N-diethyltryptamine (DET), N,N-dimethyl-5-hydroxytryptamine (bufotenine), N,N-dimethyl-4-hydroxytryptamine (psilocin), and the phosphate ester of N,N-dimethyl-4-hydroxytryptamine (psilocybin).
Because the major pharmacological effects of ibogaine are probably not those of a hallucinogen (Schneider and Siggs 1957; Turner et al. 1955; Wooley 1962) and because only a very few illicit samples have been encountered, we will not discuss the subject further.
Ergot Alkaloids
Lysergic acid is a tetracyclic compound, and as noted previously, contains an indole nucleus and belongs to the family of ergot alkaloids.
Nearly all of the known naturally occurring hallucinogens have a 3-(2-ethylamino)indole contained within the molecular structure. The assessment of a particular LSD derivative as a candidate for a future CsA involves the consideration of several points.
The most important are those attempts made by other researchers to modify the structure of LSD while retaining hallucinogenic activity.
To date, all attempts to modify the tetracyclic ring system have resulted in a loss of hallucinogenic activity. For instance, of the four possible C-8 stereoisomers only the dextro isomer of LSD is hallucinogenic (Rothlin 1957a).
Modification of the amide alkyl substituents also reduces hallucinogenic activity substantially (Usdin and Efron 1972).
Additionally, substitution with either a hydroxyl or a methoxy at the C-12 of LSD results in a compound with no hallucinogenic activity (Usdin and Efron 1972), whereas a comparably substituted methoxyindolealkylamine appears to always be hallucinogenic (Gessner and Page 1962).
The only structural modification which results in the maintenance of hallucinogenic activity on par with LSD is the substitution of either a methyl or an acetyl to the indole nitrogen (Rothlin 1957b).
The total synthesis of LSD derivatives is not simple and requires the talents of an adept synthetic chemist (Jacobs and Craig 1934; Kornfeld et al. 1954; Garbrecht 1959).
Much of the LSD produced today uses ergotamine that is obtained from legitimate commercial sources (Golden, L. personal communication).
However, if ergotamine becomes difficult to obtain from commercial sources, the ergot alkaloids can be produced easily and in large quantities by cultivating strains of the fungus Claviceps in submerged cultures (Spalla 1980).
Given the fact that structural modifications of the tetracyclic ring system are likely to result in a product with either little or no activity, and the fact that there will never be a shortage of ergot alkaloids for clandestine syntheses, it is quite unlikely that the total synthesis of LSD or derivatives thereof will become commonplace in the near term.
One final point to consider is that the CFR lists LSD and all optical, geometrical, and positional isomers of LSD under Schedule I, and lysergic acid and lysergic acid amide under Schedule III.
Because of previously noted pharmacodynamics and the imposing nature of a total synthesis, the immediate precursor of a LSD derivative synthesis will most certainly be a controlled substance, namely lysergic acid; therefore, much of the impetus for producing noncontrolled LSD derivatives is lost.
However, if the CsA amendment were not a consideration there would be a clear first choice via substitution of the indole nitrogen to create either l-alkyl or 1-acyl derivatives. Derivatives of this type most probably fall under the purview of the CsA amendment.
The N,N-methylpropyl isomer Of LSD has been the only derivative of LSD examined by the author. Derivatives of this type might seem to be an unlikely choice for a Ca due to a high probability of significant loss in hallucinogenic activity.
However, a reduction in hallucinogenic activity may become acceptable to the U. S. clandestine chemist when he notes that lysergic acid amide is listed as a Schedule III substance in the CFR; therefore, structurally similar substances of this compound are exempted from the CsA amendment.
A lucid argument can then be made that lysergic acid N,N-dimethylamide is derived from lysergic acid amide rather than LSD. Carrying this theme to the next logical step one would then assume that the 1-alkyl and 1-acyl derivatives of the N,N-dimethyl isomer would also not be controlled by the CsA amendment. At present, no known CsA of LSD has ever been encountered by the DEA. (continued on page 2)
page 1 page 2 page 3
Books Drug Identification:
Designer and Club Drugs Quick Reference Guide
The author worked as an undercover detective in rave clubs for several years. This is a condensed version of what he learned that will be of use to parents, authorities, and users alike.
It lists symptoms people look for when judging if someone is using, paraphernalia used for different designer drugs, as well it provides pictures of what various designer drugs looks like.
Drug Identification Synthetic Panics:
The Symbolic Politics of Designer Drugs
Just as every new drug creates a panic that is fueled by the media, this book looks at the panic over designer drugs created by those interested in making money off of lies and deception.
Accurate and non biased, this is worth getting for anyone who wants to know the truth. Includes chapters on; Speed Kills, The PCP Crisis, Suppressing Ecstasy, The CAT Attack, Redneck Cocaine, Methamphetamine, Rave Drugs and Rape Drugs, and much more.
Synthetic Panics
More Designer Drug Books Designer Drug books from Amazon
Designer Drug Related More Designer Drug Articles